2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.
Julia Liu, MD, professor of Medicine, Gastroenterology, Morehouse School of Medicine, discusses enrolling diverse patients in the PREEMPT CRC trial (NCT04369053) in colorectal cancer (CRC).
The PREEMPT CRC study is a prospective, multi-center, observational trial evaluating a blood-based test to detect CRC in average-risk patients receiving a routine screening colonoscopy.
Race was not used as a factor when enrolling patients on the trial, Liu says. However, at the Morehouse School of Medicine, a majority of patients are Black, which led an increased number of African American patients enrolled on the trial, Liu explains.
Clinical trials have struggled to properly enroll non-White patients, and it is a myth that Black patients do not want to participate in these studies, Liu continues. Investigators in the PREEMPT CRC trial saw Black patients eager to participate, Liu concludes.